{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:15:50Z","timestamp":1790021750076,"version":"4.0.1"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12035-026-05775-2","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T18:01:45Z","timestamp":1772474505000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Modulating LRP1 Pathways in Alzheimer\u2019s Disease: Mechanistic Insights and Emerging Therapies"],"prefix":"10.1007","volume":"63","author":[{"given":"Tehreem","family":"Mushtaq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8636-8644","authenticated-orcid":false,"given":"Huma","family":"Hameed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahtab Ahmad","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urwa","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anam","family":"Hameed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"5775_CR1","doi-asserted-by":"publisher","DOI":"10.1101\/2023.09.04.23294917","author":"SS Huang","year":"2023","unstructured":"Huang SS et al (2023) Fact check: assessing the response of ChatGPT to Alzheimer\u2019s disease statements with varying degrees of misinformation. Medrxiv. https:\/\/doi.org\/10.1101\/2023.09.04.23294917","journal-title":"Medrxiv"},{"issue":"2","key":"5775_CR2","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","volume":"7","author":"E Nichols","year":"2022","unstructured":"Nichols E et al (2022) Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health 7(2):e105\u2013e125","journal-title":"Lancet Public Health"},{"key":"5775_CR3","doi-asserted-by":"crossref","unstructured":"Deng J, and Gao\u00a0X (2024)\u00a0Analysis of genetic mechanisms, clinical characteristics and pathological changes in familial Alzheimer\u2019s disease and sporadic Alzheimer\u2019s disease. in BIO Web of Conferences. EDP Sci","DOI":"10.1051\/bioconf\/202411103001"},{"key":"5775_CR4","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1201\/9781003389699-32","volume-title":"Greenfield\u2019s Neuropathology 10e Set","author":"DR Thal","year":"2024","unstructured":"Thal DR, Murray ME, Dickson DW (2024) Alzheimer\u2019s disease (A\u03b2 and Tau proteinopathy). Greenfield\u2019s Neuropathology 10e Set. CRC Press, pp 1012\u20131041"},{"issue":"12","key":"5775_CR5","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.3390\/biomedicines9121910","volume":"9","author":"V Garc\u00eda-Morales","year":"2021","unstructured":"Garc\u00eda-Morales V et al (2021) Current understanding of the physiopathology, diagnosis and therapeutic approach to Alzheimer\u2019s disease. Biomedicines 9(12):1910","journal-title":"Biomedicines"},{"key":"5775_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.177199","volume":"987","author":"M Afzal","year":"2024","unstructured":"Afzal M et al (2024) Bioengineered exosomes: cellular membrane-camouflaged biomimetic nanocarriers for Parkinson\u2019s disease management. Eur J Pharmacol 987:177199","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"5775_CR7","doi-asserted-by":"publisher","first-page":"948","DOI":"10.3390\/pharmaceutics16070948","volume":"16","author":"S Petralla","year":"2024","unstructured":"Petralla S et al (2024) Low-density lipoprotein receptor-related protein 1 as a potential therapeutic target in Alzheimer\u2019s disease. Pharmaceutics 16(7):948","journal-title":"Pharmaceutics"},{"key":"5775_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.798334","volume":"8","author":"J-S Tan","year":"2022","unstructured":"Tan J-S et al (2022) Genetic predisposition to low-density lipoprotein cholesterol may increase risks of both individual and familial Alzheimer\u2019s disease. Front Med 8:798334","journal-title":"Front Med"},{"key":"5775_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2020.104852","volume":"141","author":"M Vasefi","year":"2020","unstructured":"Vasefi M et al (2020) Environmental toxins and Alzheimer\u2019s disease progression. Neurochem Int 141:104852","journal-title":"Neurochem Int"},{"issue":"1","key":"5775_CR10","first-page":"413808","volume":"2013","author":"A Prasansuklab","year":"2013","unstructured":"Prasansuklab A, Tencomnao T (2013) Amyloidosis in Alzheimer\u2019s disease: the toxicity of amyloid beta (A\u03b2), mechanisms of its accumulation and implications of medicinal plants for therapy. Evid Based Complement Alternat Med 2013(1):413808","journal-title":"Evid Based Complement Alternat Med"},{"issue":"1","key":"5775_CR11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s13195-025-01840-5","volume":"17","author":"T-T Pan","year":"2025","unstructured":"Pan T-T et al (2025) Endothelial delivery of simvastatin by LRP1-targeted nanoparticles ameliorates pathogenesis of Alzheimer\u2019s disease in a mouse model. Alzheimers Res Ther 17(1):193","journal-title":"Alzheimers Res Ther"},{"issue":"56-57","key":"5775_CR12","first-page":"70","volume":"548","author":"N Bari\u0107","year":"2021","unstructured":"Bari\u0107 N (2021) The role of the LRP1 receptor in the draining of amyloid beta (A\u03b2) peptide across the blood brain barrier (BBB). Rad Hrv Akad Znan Umjet Med Znan 548(56\u201357):70\u201383","journal-title":"Rad Hrv Akad Znan Umjet Med Znan"},{"issue":"11","key":"5775_CR13","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.4103\/1673-5374.335829","volume":"17","author":"Y-L Zhang","year":"2022","unstructured":"Zhang Y-L et al (2022) The relationship between amyloid-beta and brain capillary endothelial cells in Alzheimer\u2019s disease. Neural Regen Res 17(11):2355\u20132363","journal-title":"Neural Regen Res"},{"key":"5775_CR14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.neurobiolaging.2023.02.013","volume":"127","author":"H Na","year":"2023","unstructured":"Na H et al (2023) Peripheral apolipoprotein E proteins and their binding to LRP1 antagonize Alzheimer\u2019s disease pathogenesis in the brain during peripheral chronic inflammation. Neurobiol Aging 127:54\u201369","journal-title":"Neurobiol Aging"},{"issue":"7715","key":"5775_CR15","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1038\/d41586-018-05719-4","volume":"559","author":"S Makin","year":"2018","unstructured":"Makin S (2018) The amyloid hypothesis on trial. Nature 559(7715):S4\u2013S4","journal-title":"Nature"},{"key":"5775_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cells11243994","author":"K Ando","year":"2022","unstructured":"Ando K et al (2022) PICALM and Alzheimer\u2019s disease: an update and perspectives. Cells. https:\/\/doi.org\/10.3390\/cells11243994","journal-title":"Cells"},{"key":"5775_CR17","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.3389\/fnins.2019.01154","volume":"13","author":"H Hillen","year":"2019","unstructured":"Hillen H (2019) The beta amyloid dysfunction (BAD) hypothesis for Alzheimer\u2019s disease. Front Neurosci 13:1154","journal-title":"Front Neurosci"},{"issue":"6","key":"5775_CR18","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/mds.26624","volume":"31","author":"G Forloni","year":"2016","unstructured":"Forloni G et al (2016) Oligomeropathies and pathogenesis of Alzheimer and Parkinson\u2019s diseases. Mov Disord 31(6):771\u2013781","journal-title":"Mov Disord"},{"issue":"2","key":"5775_CR19","doi-asserted-by":"publisher","first-page":"87","DOI":"10.5114\/fn.2019.85929","volume":"57","author":"RA Armstrong","year":"2019","unstructured":"Armstrong RA (2019) Risk factors for Alzheimer\u2019s disease. Folia Neuropathol 57(2):87\u2013105","journal-title":"Folia Neuropathol"},{"key":"5775_CR20","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s12272-013-0036-3","volume":"36","author":"P Anand","year":"2013","unstructured":"Anand P, Singh B (2013) A review on cholinesterase inhibitors for Alzheimer\u2019s disease. Arch Pharm Res 36:375\u2013399","journal-title":"Arch Pharm Res"},{"issue":"4","key":"5775_CR21","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.3390\/ijms22042022","volume":"22","author":"LO Soto-Rojas","year":"2021","unstructured":"Soto-Rojas LO et al (2021) The neurovascular unit dysfunction in Alzheimer\u2019s disease. Int J Mol Sci 22(4):2022","journal-title":"Int J Mol Sci"},{"issue":"6","key":"5775_CR22","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00401-023-02559-z","volume":"145","author":"Y Cheng","year":"2023","unstructured":"Cheng Y et al (2023) Physiological \u03b2-amyloid clearance by the liver and its therapeutic potential for Alzheimer\u2019s disease. Acta Neuropathol 145(6):717\u2013731","journal-title":"Acta Neuropathol"},{"key":"5775_CR23","doi-asserted-by":"crossref","unstructured":"Tekin E, and Din\u00e7er\u00a0S (2023)\u00a0Inadequate amyloid clearance in Alzheimer\u2019s disease: the possible role of TTR transporter protein and LRP-1 receptor. Gazi Med J 34(1)","DOI":"10.12996\/gmj.2023.23"},{"key":"5775_CR24","unstructured":"Chen J (2025) Nanomedicine modulation of endothelial low-density lipoprotein receptor-related protein 1 at the blood brain barrier for Alzheimer\u2019s disease therapy.\u00a0UCL (University College London)."},{"issue":"10","key":"5775_CR25","doi-asserted-by":"publisher","first-page":"2003937","DOI":"10.1002\/advs.202003937","volume":"8","author":"W Zhang","year":"2021","unstructured":"Zhang W et al (2021) Development of polymeric nanoparticles for blood\u2013brain barrier transfer\u2014strategies and challenges. Adv Sci 8(10):2003937","journal-title":"Adv Sci"},{"issue":"16","key":"5775_CR26","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.3390\/jcm10163571","volume":"10","author":"A Benitez Amaro","year":"2021","unstructured":"Benitez Amaro A et al (2021) Apolipoprotein and LRP1-based peptides as new therapeutic tools in atherosclerosis. J Clin Med 10(16):3571","journal-title":"J Clin Med"},{"issue":"9","key":"5775_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0285834","volume":"18","author":"A Henry","year":"2023","unstructured":"Henry A et al (2023) The endocytic receptor protein LRP-1 modulate P-glycoprotein mediated drug resistance in MCF-7 cells. PLoS One 18(9):e0285834","journal-title":"PLoS One"},{"key":"5775_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/os.70035","author":"Y Wu","year":"2025","unstructured":"Wu Y et al (2025) LRP1 mediates endocytosis activity and is a potential therapeutic target in osteoarthritis. Orthop Surg. https:\/\/doi.org\/10.1111\/os.70035","journal-title":"Orthop Surg"},{"key":"5775_CR29","unstructured":"Frank CJ (2023) Effects of aerobic exercise on rage and LRP1 in STZ and HFD models of diabetes: relationship with cognitive function and A\u03b2 clearance.\u00a0State University of New York at Albany"},{"issue":"12","key":"5775_CR30","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1007\/s11095-017-2267-3","volume":"34","author":"SE Storck","year":"2017","unstructured":"Storck SE, Pietrzik CU (2017) Endothelial LRP1\u2013a potential target for the treatment of Alzheimer\u2019s disease: theme: drug discovery, development and delivery in Alzheimer\u2019s disease guest editor: Davide Brambilla. Pharm Res 34(12):2637\u20132651","journal-title":"Pharm Res"},{"key":"5775_CR31","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.2147\/IJN.S200490","volume":"14","author":"S Tiwari","year":"2019","unstructured":"Tiwari S et al (2019) Alzheimer\u2019s disease: pathogenesis, diagnostics, and therapeutics. Int J Nanomedicine 14:5541\u20135554","journal-title":"Int J Nanomedicine"},{"issue":"1","key":"5775_CR32","doi-asserted-by":"publisher","first-page":"8463","DOI":"10.1038\/s41467-023-44319-3","volume":"14","author":"J Lee","year":"2023","unstructured":"Lee J et al (2023) ANKS1A regulates LDL receptor-related protein 1 (LRP1)-mediated cerebrovascular clearance in brain endothelial cells. Nat Commun 14(1):8463","journal-title":"Nat Commun"},{"key":"5775_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27196696","author":"AC di Polidoro","year":"2022","unstructured":"di Polidoro AC et al (2022) Revealing Angiopep-2\/LRP1 molecular interaction for optimal delivery to glioblastoma (GBM). Molecules. https:\/\/doi.org\/10.3390\/molecules27196696","journal-title":"Molecules"},{"issue":"1","key":"5775_CR34","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12974-025-03443-1","volume":"22","author":"J Han","year":"2025","unstructured":"Han J et al (2025) Extracellular vesicles as therapeutic modulators of neuroinflammation in Alzheimer\u2019s disease: a focus on signaling mechanisms. J Neuroinflammation 22(1):120","journal-title":"J Neuroinflammation"},{"key":"5775_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1102809","volume":"15","author":"JA Sousa","year":"2023","unstructured":"Sousa JA et al (2023) Reconsidering the role of blood-brain barrier in Alzheimer\u2019s disease: from delivery to target. Front Aging Neurosci 15:1102809","journal-title":"Front Aging Neurosci"},{"issue":"5","key":"5775_CR36","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1111\/j.1471-4159.2010.07002.x","volume":"115","author":"BV Zlokovic","year":"2010","unstructured":"Zlokovic BV et al (2010) Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer\u2019s amyloid \u03b2-peptide elimination from the brain. J Neurochem 115(5):1077\u20131089","journal-title":"J Neurochem"},{"issue":"2","key":"5775_CR37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s12031-025-02339-2","volume":"75","author":"W Yang","year":"2025","unstructured":"Yang W, Wei Z, Wang T (2025) Unraveling the role of LRP1 in Alzheimer\u2019s disease: a focus on A\u03b2 clearance and the liver-brain axis. J Mol Neurosci 75(2):43","journal-title":"J Mol Neurosci"},{"key":"5775_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2024.106570","volume":"199","author":"DV Chandrashekar","year":"2024","unstructured":"Chandrashekar DV et al (2024) Hepatic LRP-1 plays an important role in amyloidosis in Alzheimer\u2019s disease mice: potential role in chronic heavy alcohol feeding. Neurobiol Dis 199:106570","journal-title":"Neurobiol Dis"},{"issue":"3","key":"5775_CR39","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3390\/neuroglia4030015","volume":"4","author":"JVR Cruz","year":"2023","unstructured":"Cruz JVR et al (2023) The role of astrocytes and blood\u2013brain barrier disruption in Alzheimer\u2019s disease. Neuroglia 4(3):209\u2013221","journal-title":"Neuroglia"},{"key":"5775_CR40","doi-asserted-by":"crossref","unstructured":"Liu C et al (2024) Insight into cerebral microvessel endothelial regulation of cognitive impairment: a systematic review of the causes and consequences. Exp Neurol\u00a0 p. 115116","DOI":"10.1016\/j.expneurol.2024.115116"},{"issue":"1","key":"5775_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12987-021-00260-5","volume":"18","author":"SE Storck","year":"2021","unstructured":"Storck SE, Kurtyka M, Pietrzik CU (2021) Brain endothelial LRP1 maintains blood\u2013brain barrier integrity. Fluids Barriers CNS 18(1):27","journal-title":"Fluids Barriers CNS"},{"key":"5775_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2022.105417","volume":"160","author":"P Xue","year":"2022","unstructured":"Xue P et al (2022) The role of LRP1 in A\u03b2 efflux transport across the blood-brain barrier and cognitive dysfunction in diabetes mellitus. Neurochem Int 160:105417","journal-title":"Neurochem Int"},{"key":"5775_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116643","volume":"231","author":"W Li","year":"2025","unstructured":"Li W et al (2025) The LDL receptor-related protein 1: mechanisms and roles in promoting A\u03b2 efflux transporter in Alzheimer\u2019s disease. Biochem Pharmacol 231:116643","journal-title":"Biochem Pharmacol"},{"key":"5775_CR44","doi-asserted-by":"crossref","unstructured":"Carreca A, Pravat\u00e0 V, Markham M, Bonelli S, Murphy G, Nagase H, Troeberg L, & Scilabra S (2020) Timp-3 facilitates binding of target metalloproteinases to the endocytic receptor lrp-1 and promotes scavenging of mmp-1. Sci Rep 10(1): 12067","DOI":"10.1038\/s41598-020-69008-9"},{"key":"5775_CR45","doi-asserted-by":"crossref","unstructured":"Kang K, Lee S, & Kim S (2005) Molecular mechanism of nrf2 activation by oxidative stress. Antioxid Redox Signal 7(11-12): 1664\u20131673","DOI":"10.1089\/ars.2005.7.1664"},{"issue":"1","key":"5775_CR46","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12964-022-00906-3","volume":"20","author":"F Pouremamali","year":"2022","unstructured":"Pouremamali F et al (2022) An update of Nrf2 activators and inhibitors in cancer prevention\/promotion. Cell Commun Signal 20(1):100","journal-title":"Cell Commun Signal"},{"issue":"2","key":"5775_CR47","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s11064-022-03755-1","volume":"48","author":"V Sharma","year":"2023","unstructured":"Sharma V et al (2023) Brain-derived neurotrophic factor: a novel dynamically regulated therapeutic modulator in neurological disorders. Neurochem Res 48(2):317\u2013339","journal-title":"Neurochem Res"},{"issue":"6","key":"5775_CR48","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1159\/000517794","volume":"64","author":"HP Scholl","year":"2021","unstructured":"Scholl HP et al (2021) The use of neuroprotective agents in treating geographic atrophy. Ophthalmic Res 64(6):888\u2013902","journal-title":"Ophthalmic Res"},{"issue":"4","key":"5775_CR49","doi-asserted-by":"publisher","first-page":"3866","DOI":"10.3390\/ijms24043866","volume":"24","author":"Y El Ouaamari","year":"2023","unstructured":"El Ouaamari Y et al (2023) Neurotrophic factors as regenerative therapy for neurodegenerative diseases: current status, challenges and future perspectives. Int J Mol Sci 24(4):3866","journal-title":"Int J Mol Sci"},{"issue":"3","key":"5775_CR50","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s10571-022-01230-7","volume":"43","author":"I Aillaud","year":"2023","unstructured":"Aillaud I, Funke SA (2023) Tau aggregation inhibiting peptides as potential therapeutics for Alzheimer disease. Cell Mol Neurobiol 43(3):951\u2013961","journal-title":"Cell Mol Neurobiol"},{"issue":"12","key":"5775_CR51","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41582-023-00883-2","volume":"19","author":"EE Congdon","year":"2023","unstructured":"Congdon EE et al (2023) Tau-targeting therapies for Alzheimer disease: current status and future directions. Nat Rev Neurol 19(12):715\u2013736","journal-title":"Nat Rev Neurol"},{"key":"5775_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13010038","author":"GR Topal","year":"2020","unstructured":"Topal GR et al (2020) ApoE-targeting increases the transfer of solid lipid nanoparticles with donepezil cargo across a culture model of the blood-brain barrier. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics13010038","journal-title":"Pharmaceutics"},{"issue":"1","key":"5775_CR53","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/alz.12728","volume":"19","author":"M Lozupone","year":"2023","unstructured":"Lozupone M et al (2023) Does the imbalance in the apolipoprotein E isoforms underlie the pathophysiological process of sporadic Alzheimer\u2019s disease? Alzheimers Dement 19(1):353\u2013368","journal-title":"Alzheimers Dement"},{"issue":"5","key":"5775_CR54","doi-asserted-by":"publisher","first-page":"e512","DOI":"10.1212\/NXG.0000000000000512","volume":"6","author":"C Reitz","year":"2020","unstructured":"Reitz C, Rogaeva E, Beecham GW (2020) Late-onset vs nonmendelian early-onset Alzheimer disease: a distinction without a difference? Neurol Genet 6(5):e512","journal-title":"Neurol Genet"},{"key":"5775_CR55","doi-asserted-by":"crossref","unstructured":"Hameed H, Faheem S, Younas K, Jamshaid M, Ereej N, Hameed A, Munir R, & Khokhar R (2024) A comprehensive review on lipid-based nanoparticles via nose to brain targeting as a novel approach. J microencapsul 41","DOI":"10.1080\/02652048.2024.2404414"},{"issue":"1","key":"5775_CR56","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12951-025-03109-3","volume":"23","author":"Y-J Jang","year":"2025","unstructured":"Jang Y-J et al (2025) Drug delivery strategies with lipid-based nanoparticles for Alzheimer\u2019s disease treatment. Journal of nanobiotechnology 23(1):99","journal-title":"Journal of nanobiotechnology"},{"issue":"4","key":"5775_CR57","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s13346-024-01710-x","volume":"15","author":"SA Vahab","year":"2025","unstructured":"Vahab SA, V VK, Kumar VS (2025) Exosome-based drug delivery systems for enhanced neurological therapeutics. Drug Deliv Transl Res 15(4):1121\u20131138","journal-title":"Drug Deliv Transl Res"},{"key":"5775_CR58","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.neurobiolaging.2019.10.025","volume":"89","author":"CE Shepherd","year":"2020","unstructured":"Shepherd CE et al (2020) Intracellular and secreted forms of clusterin are elevated early in Alzheimer\u2019s disease and associate with both A\u03b2 and tau pathology. Neurobiol Aging 89:129\u2013131","journal-title":"Neurobiol Aging"},{"issue":"2","key":"5775_CR59","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/1753-0407.13352","volume":"15","author":"H Zhao","year":"2023","unstructured":"Zhao H et al (2023) Thiazolidinedione use is associated with reduced risk of dementia in patients with type 2 diabetes mellitus: a retrospective cohort study. J Diabetes 15(2):97\u2013109","journal-title":"J Diabetes"},{"issue":"9","key":"5775_CR60","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1021\/acs.chemrev.3c00705","volume":"124","author":"MA Beach","year":"2024","unstructured":"Beach MA et al (2024) Polymeric nanoparticles for drug delivery. Chem Rev 124(9):5505\u20135616","journal-title":"Chem Rev"},{"key":"5775_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12987-016-0038-x","volume":"13","author":"B Shackleton","year":"2016","unstructured":"Shackleton B, Crawford F, Bachmeier C (2016) Inhibition of ADAM10 promotes the clearance of A\u03b2 across the BBB by reducing LRP1 ectodomain shedding. Fluids Barriers CNS 13:1\u20139","journal-title":"Fluids Barriers CNS"},{"key":"5775_CR62","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jconrel.2021.05.032","volume":"335","author":"Y Mirchandani","year":"2021","unstructured":"Mirchandani Y, Patravale VB, S B (2021) Solid lipid nanoparticles for hydrophilic drugs. J Control Release 335:457\u2013464","journal-title":"J Control Release"},{"key":"5775_CR63","doi-asserted-by":"publisher","first-page":"8296","DOI":"10.1007\/s12035-019-01672-z","volume":"56","author":"B Shackleton","year":"2019","unstructured":"Shackleton B et al (2019) Influence of matrix metallopeptidase 9 on beta-amyloid elimination across the blood-brain barrier. Mol Neurobiol 56:8296\u20138305","journal-title":"Mol Neurobiol"},{"key":"5775_CR64","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.addr.2020.07.002","volume":"154\u2013155","author":"S Shah","year":"2020","unstructured":"Shah S et al (2020) Liposomes: advancements and innovation in the manufacturing process. Adv Drug Deliv Rev 154\u2013155:102\u2013122","journal-title":"Adv Drug Deliv Rev"},{"key":"5775_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-021-00500-0","volume":"16","author":"B Bhargavan","year":"2021","unstructured":"Bhargavan B et al (2021) CCR5 antagonist reduces HIV-induced amyloidogenesis, tau pathology, neurodegeneration, and blood-brain barrier alterations in HIV-infected hu-PBL-NSG mice. Mol Neurodegener 16:1\u201323","journal-title":"Mol Neurodegener"},{"issue":"1","key":"5775_CR66","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s12035-018-1045-5","volume":"56","author":"S Paik","year":"2019","unstructured":"Paik S, Somvanshi RK, Kumar U (2019) Somatostatin maintains permeability and integrity of blood-brain barrier in \u03b2-amyloid induced toxicity. Mol Neurobiol 56(1):292\u2013306","journal-title":"Mol Neurobiol"},{"issue":"Pt 2","key":"5775_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.131401","volume":"267","author":"H Hatami","year":"2024","unstructured":"Hatami H, Rahiman N, Mohammadi M (2024) Oligonucleotide based nanogels for cancer therapeutics. Int J Biol Macromol 267(Pt 2):131401","journal-title":"Int J Biol Macromol"},{"key":"5775_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.118814","volume":"573","author":"AP Dias","year":"2020","unstructured":"Dias AP et al (2020) Dendrimers in the context of nanomedicine. Int J Pharm 573:118814","journal-title":"Int J Pharm"},{"key":"5775_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcn.2019.103390","volume":"99","author":"CC Gali","year":"2019","unstructured":"Gali CC et al (2019) Amyloid-beta impairs insulin signaling by accelerating autophagy-lysosomal degradation of LRP-1 and IR-\u03b2 in blood-brain barrier endothelial cells in vitro and in 3XTg-AD mice. Mol Cell Neurosci 99:103390","journal-title":"Mol Cell Neurosci"},{"issue":"2","key":"5775_CR70","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/jnc.15112","volume":"156","author":"T Soares Martins","year":"2021","unstructured":"Soares Martins T et al (2021) Diagnostic and therapeutic potential of exosomes in Alzheimer\u2019s disease. J Neurochem 156(2):162\u2013181","journal-title":"J Neurochem"},{"issue":"11","key":"5775_CR71","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s43587-023-00516-9","volume":"3","author":"X Guo","year":"2023","unstructured":"Guo X et al (2023) Chiral nanoparticle-remodeled gut microbiota alleviates neurodegeneration via the gut-brain axis. Nat Aging 3(11):1415\u20131429","journal-title":"Nat Aging"},{"issue":"2","key":"5775_CR72","doi-asserted-by":"publisher","first-page":"e180723218848","DOI":"10.2174\/1570163820666230718123544","volume":"21","author":"M Kurup","year":"2024","unstructured":"Kurup M et al (2024) The biogenetic synthesis of metallic nanoparticles and the role they play in the anti-inflammatory drug treatment. Curr Drug Discov Technol 21(2):e180723218848","journal-title":"Curr Drug Discov Technol"},{"issue":"1","key":"5775_CR73","doi-asserted-by":"publisher","first-page":"e898","DOI":"10.1097\/PR9.0000000000000898","volume":"6","author":"P Garc\u00eda-Fern\u00e1ndez","year":"2021","unstructured":"Garc\u00eda-Fern\u00e1ndez P, \u00dc\u00e7eyler N, Sommer C (2021) From the low-density lipoprotein receptor\u2013related protein 1 to neuropathic pain: a potentially novel target. Pain Rep 6(1):e898","journal-title":"Pain Rep"},{"key":"5775_CR74","doi-asserted-by":"crossref","unstructured":"Liu Z, Andraska E, Akinbode D, Mars W, & Alvidrez R (2022) Lrp1 in the vascular wall. Curr Pathobiology Rep 10(3): p 23\u201334","DOI":"10.1007\/s40139-022-00231-x"},{"key":"5775_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17162628","author":"S Park","year":"2025","unstructured":"Park S et al (2025) Nanoparticle-based delivery strategies for combating drug resistance in cancer therapeutics. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers17162628","journal-title":"Cancers (Basel)"},{"issue":"2","key":"5775_CR76","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3233\/JAD-191320","volume":"78","author":"L Gao","year":"2020","unstructured":"Gao L et al (2020) Relationship between peripheral transport proteins and plasma amyloid-\u03b2 in patients with Alzheimer\u2019s disease were different from cognitively normal controls: a propensity score matching analysis. J Alzheimers Dis 78(2):699\u2013709","journal-title":"J Alzheimers Dis"},{"key":"5775_CR77","doi-asserted-by":"crossref","unstructured":"Hameed H, Khan M, Paiva-Santos A, Faheem S, Khalid A, Majid M, Adnan A, & Rana F (2024) Liposomes like advanced drug carriers: from fundamentals to pharmaceutical applications. J Microencapsul 41","DOI":"10.1080\/02652048.2024.2376116"},{"issue":"7","key":"5775_CR78","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1194\/jlr.R075796","volume":"58","author":"M Shinohara","year":"2017","unstructured":"Shinohara M et al (2017) Role of LRP1 in the pathogenesis of Alzheimer\u2019s disease: evidence from clinical and preclinical studies. J Lipid Res 58(7):1267\u20131281","journal-title":"J Lipid Res"},{"key":"5775_CR79","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3389\/fnagi.2018.00050","volume":"10","author":"Y Pan","year":"2018","unstructured":"Pan Y et al (2018) Royal jelly reduces cholesterol levels, ameliorates A\u03b2 pathology and enhances neuronal metabolic activities in a rabbit model of Alzheimer\u2019s disease. Front Aging Neurosci 10:50","journal-title":"Front Aging Neurosci"},{"key":"5775_CR80","doi-asserted-by":"crossref","unstructured":"Wang K, Yang R, Li J, Wang H, Wan, L, & He J (2025) Nanocarrier-based targeted drug delivery for alzheimer\u2019s disease: addressing neuroinflammation and enhancing clinical translation. Front Pharm 16: p. 1591438","DOI":"10.3389\/fphar.2025.1591438"},{"key":"5775_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2025.e00722","author":"L Chen","year":"2025","unstructured":"Chen L et al (2025) Engineered nanoplatforms for brain-targeted co-delivery of phytochemicals in Alzheimer\u2019s disease: rational design, blood-brain barrier penetration, and multi-target therapeutic synergy. Neurotherapeutics. https:\/\/doi.org\/10.1016\/j.neurot.2025.e00722","journal-title":"Neurotherapeutics"},{"key":"5775_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2025.106913","volume":"108","author":"AA Ashour","year":"2025","unstructured":"Ashour AA et al (2025) Lactoferrin coated flaxosules for the effective co-delivery of piperine and flaxseed oil in breast cancer: a mechanistic crosstalk between apoptosis and autophagy. J Drug Deliv Sci Technol 108:106913","journal-title":"J Drug Deliv Sci Technol"},{"issue":"1","key":"5775_CR83","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1172\/JCI81108","volume":"126","author":"SE Storck","year":"2016","unstructured":"Storck SE et al (2016) Endothelial LRP1 transports amyloid-\u03b2 1\u201342 across the blood-brain barrier. J Clin Investig 126(1):123\u2013136","journal-title":"J Clin Investig"},{"issue":"1","key":"5775_CR84","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1186\/s12951-025-03528-2","volume":"23","author":"N Sanadgol","year":"2025","unstructured":"Sanadgol N et al (2025) Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acids: advances and challenges. J Nanobiotechnology 23(1):453","journal-title":"J Nanobiotechnology"},{"key":"5775_CR85","doi-asserted-by":"crossref","unstructured":"Liu C, Hu J, Zhao N, Wang J, Wang, N, Cirrito J, Kanekiyo T, Holtzman D, & Bu G (2017) Astrocytic lrp1 mediates brain a\u03b2 clearance and impacts amyloid deposition. The J Neurosci 37(15): 4023\u20134031","DOI":"10.1523\/JNEUROSCI.3442-16.2017"},{"key":"5775_CR86","doi-asserted-by":"publisher","unstructured":"Hameed H, Zaman M, Faheem S, Khan MA, Ghumman SA, Mehboob T, Tabassam N (2025) Ethical issues in genome editing.\u00a0In: Ali A, Shafi que F, editors. Gene Editing by CRISPR-Cas. Boca Raton (FL): CRC Press. p. 283\u2013299.\u00a0\u00a0https:\/\/doi.org\/10.1201\/9781003537151-12.","DOI":"10.1201\/9781003537151-12."},{"key":"5775_CR87","doi-asserted-by":"crossref","unstructured":"Yamanaka Y, Faghihi M, Magistri M, Alvarez-Garcia O, Lotz M, & Wahlestedt C (2015) Antisense rna controls lrp1 sense transcript expression through interaction with a chromatin-associated protein, hmgb2. Cell Rep 11(6): 967\u2013976","DOI":"10.1016\/j.celrep.2015.04.011"},{"issue":"7","key":"5775_CR88","doi-asserted-by":"publisher","first-page":"781","DOI":"10.3390\/antiox14070781","volume":"14","author":"I Raffaele","year":"2025","unstructured":"Raffaele I et al (2025) CRISPR\/Cas9 and iPSC-based therapeutic approaches in Alzheimer\u2019s disease. Antioxidants 14(7):781","journal-title":"Antioxidants"},{"issue":"1","key":"5775_CR89","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1186\/s12951-025-03415-w","volume":"23","author":"S Liu","year":"2025","unstructured":"Liu S et al (2025) Advances in brain-targeted delivery strategies and natural product-mediated enhancement of blood\u2013brain barrier permeability. J Nanobiotechnology 23(1):382","journal-title":"J Nanobiotechnology"},{"key":"5775_CR90","doi-asserted-by":"crossref","unstructured":"Nikolakopoulou A et al (2021) Endothelial lrp1 protects against neurodegeneration by blocking cyclophilin a. J Exp Med 218(4)","DOI":"10.1084\/jem.20202207"},{"issue":"7","key":"5775_CR91","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011884","volume":"5","author":"RA Fuentealba","year":"2010","unstructured":"Fuentealba RA et al (2010) Low-density lipoprotein receptor-related protein 1 (LRP1) mediates neuronal Abeta42 uptake and lysosomal trafficking. PLoS ONE 5(7):e11884","journal-title":"PLoS ONE"},{"issue":"6","key":"5775_CR92","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00401-023-02559-z","volume":"145","author":"Y Cheng","year":"2023","unstructured":"Cheng Y et al (2023) Physiological \u03b2-amyloid clearance by the liver and its therapeutic potential for Alzheimer\u2019s disease. Acta Neuropathol 145(6):717\u2013731","journal-title":"Acta Neuropathol"},{"issue":"7803","key":"5775_CR93","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41586-020-2156-5","volume":"580","author":"JN Rauch","year":"2020","unstructured":"Rauch JN et al (2020) LRP1 is a master regulator of tau uptake and spread. Nature 580(7803):381\u2013385","journal-title":"Nature"},{"key":"5775_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100715","author":"JM Cooper","year":"2021","unstructured":"Cooper JM  et al (2021) Regulation of tau internalization, degradation, and seeding by lrp1 reveals multiple pathways for tau catabolism. The J biol chem 296","journal-title":"J Biol Chem"},{"key":"5775_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111667","volume":"139","author":"Z He","year":"2021","unstructured":"He Z et al (2021) The molecular mechanism of LRP1 in physiological vascular homeostasis and signal transduction pathways. Biomed Pharmacother 139:111667","journal-title":"Biomed Pharmacother"},{"key":"5775_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40035-020-00195-1","volume":"9","author":"Y Cheng","year":"2020","unstructured":"Cheng Y, Tian D-Y, Wang Y-J (2020) Peripheral clearance of brain-derived A\u03b2 in Alzheimer\u2019s disease: pathophysiology and therapeutic perspectives. Transl Neurodegener 9:1\u201311","journal-title":"Transl Neurodegener"},{"issue":"8","key":"5775_CR97","doi-asserted-by":"publisher","first-page":"11815","DOI":"10.1021\/acsnano.1c10034","volume":"16","author":"LL Israel","year":"2022","unstructured":"Israel LL et al (2022) Signature effects of vector-guided systemic nano bioconjugate delivery across blood-brain barrier of normal, Alzheimer\u2019s, and tumor mouse models. ACS Nano 16(8):11815\u201311832","journal-title":"ACS Nano"},{"issue":"4","key":"5775_CR98","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20202207","volume":"218","author":"AM Nikolakopoulou","year":"2021","unstructured":"Nikolakopoulou AM et al (2021) Endothelial LRP1 protects against neurodegeneration by blocking cyclophilin A. J Exp Med 218(4):e20202207","journal-title":"J Exp Med"},{"key":"5775_CR99","doi-asserted-by":"crossref","unstructured":"Chen K et al (2024) Single-cell data unveil the multifaceted role of LRP1 in Alzheimer\u2019s disease pathogenesis","DOI":"10.21203\/rs.3.rs-3827465\/v1"},{"key":"5775_CR100","doi-asserted-by":"crossref","unstructured":"Ju Y, Gu L, Hu M, Zheng M, Zhou X, Li Q, & Zhang X (2023) Andrographolide exerts a neuroprotective effect by regulating the lrp1-mediated ppar\u03b3\/nf-\u03bab pathway. Eur J Pharmacol 951: 175756","DOI":"10.1016\/j.ejphar.2023.175756"},{"key":"5775_CR101","doi-asserted-by":"publisher","unstructured":"Fung, KYY et al (2024) Apolipoprotein A1 and high-density lipoprotein limit low-density lipoprotein transcytosis by binding SR-B1.\u201d Journal of lipid research vol. 65,4: 100530. https:\/\/doi.org\/10.1016\/j.jlr.2024.100530","DOI":"10.1016\/j.jlr.2024.100530"},{"key":"5775_CR102","doi-asserted-by":"crossref","unstructured":"Lee H et al (2023) Anks1a-deficiency aberrantly increases the entry of the protein transport machinery into the ependymal cilia. Mol Cells 46(12): 757\u2013763","DOI":"10.14348\/molcells.2023.0153"},{"key":"5775_CR103","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16070948","author":"S Petralla","year":"2024","unstructured":"Petralla S et al (2024) Low-density lipoprotein receptor-related protein 1 as a potential therapeutic target in Alzheimer\u2019s disease. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics16070948","journal-title":"Pharmaceutics"},{"key":"5775_CR104","doi-asserted-by":"crossref","unstructured":"Hsu H et al (2021) Inflammatory cytokine il-1\u03b2 downregulates endothelial lrp1 via microrna-mediated gene silencing. Neurosci 453: 69\u201380","DOI":"10.1016\/j.neuroscience.2020.11.021"},{"key":"5775_CR105","doi-asserted-by":"publisher","DOI":"10.3390\/biom11121769","author":"L Toma","year":"2021","unstructured":"Toma L et al (2021) CRISPR\/dCas9 transcriptional activation of endogenous apolipoprotein AI and paraoxonase 1 in enterocytes alleviates endothelial cell dysfunction. Biomolecules. https:\/\/doi.org\/10.3390\/biom11121769","journal-title":"Biomolecules"},{"key":"5775_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2022.105417","volume":"160","author":"X P","year":"2022","unstructured":"P X et al (2022) The role of LRP1 in A\u03b2 efflux transport across the blood-brain barrier and cognitive dysfunction in diabetes mellitus. Neurochem Int 160:105417","journal-title":"Neurochem Int"},{"key":"5775_CR107","doi-asserted-by":"crossref","unstructured":"Chen J et al (2025) Rapid amyloid-\u03b2 clearance and cognitive recovery through multivalent modulation of blood\u2013brain barrier transport. Signal Transduct Target Ther 10(1): p. 331","DOI":"10.1038\/s41392-025-02426-1"},{"key":"5775_CR108","doi-asserted-by":"crossref","unstructured":"Belaidi AA, Bush AI, & Ayton S (2025) Apolipoprotein e in alzheimer\u2019s disease: molecular insights and therapeutic opportunities. Mol Neurodegener 20(1): p. 47","DOI":"10.1186\/s13024-025-00843-y"},{"issue":"1","key":"5775_CR109","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13024-022-00574-4","volume":"17","author":"A-C Raulin","year":"2022","unstructured":"Raulin A-C et al (2022) ApoE in Alzheimer\u2019s disease: pathophysiology and therapeutic strategies. Mol Neurodegener 17(1):72","journal-title":"Mol Neurodegener"},{"key":"5775_CR110","doi-asserted-by":"crossref","unstructured":"Correale J, Mattera V, & Pasquini JM (2026) Intranasal delivery route for neurodegenerative diseases: recent insights and future directions. Drug Deliv Transl Res  p. 1-19","DOI":"10.1007\/s13346-025-01919-4"},{"key":"5775_CR111","doi-asserted-by":"crossref","unstructured":"Cummings JL, Burstein AH, & Fillit H (2025) Alzheimer combination therapies: overview and scenarios. The Journal of Prevention of Alzheimer\u2019s Disease, 12(10): p.100328","DOI":"10.1016\/j.tjpad.2025.100328"},{"issue":"6","key":"5775_CR112","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1007\/s00415-024-12329-w","volume":"271","author":"H Tao","year":"2024","unstructured":"Tao H, Gao B (2024) Exosomes for neurodegenerative diseases: diagnosis and targeted therapy. J Neurol 271(6):3050\u20133062","journal-title":"J Neurol"},{"key":"5775_CR113","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.790863","volume":"13","author":"P Gao","year":"2021","unstructured":"Gao P et al (2021) Diagnostic and therapeutic potential of exosomes in neurodegenerative diseases. Frontiers in Aging Neuroscience 13:790863","journal-title":"Frontiers in Aging Neuroscience"},{"issue":"1","key":"5775_CR114","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13024-025-00872-7","volume":"20","author":"H Hering","year":"2025","unstructured":"Hering H et al (2025) A manifesto for Alzheimer\u2019s disease drug discovery in the era of disease-modifying therapies. Mol Neurodegener 20(1):88","journal-title":"Mol Neurodegener"},{"key":"5775_CR115","doi-asserted-by":"publisher","DOI":"10.2174\/0113895575301011240407082559","author":"N Ereej","year":"2024","unstructured":"Ereej N et al (2024) Nanoparticle-based gene therapy for neurodegenerative disorders. Mini-Rev Med Chem. https:\/\/doi.org\/10.2174\/0113895575301011240407082559","journal-title":"Mini-Rev Med Chem"},{"issue":"9","key":"5775_CR116","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.1073\/pnas.1112209109","volume":"109","author":"N Sehgal","year":"2012","unstructured":"Sehgal N et al (2012) Withania somnifera reverses Alzheimer\u2019s disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc Natl Acad Sci U S A 109(9):3510\u20133515","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"5775_CR117","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.jalz.2014.11.009","volume":"11","author":"MC Morris","year":"2015","unstructured":"Morris MC et al (2015) MIND diet associated with reduced incidence of Alzheimer\u2019s disease. Alzheimers Dement 11(9):1007\u20131014","journal-title":"Alzheimers Dement"},{"key":"5775_CR118","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3389\/fcvm.2019.00051","volume":"6","author":"N Potere","year":"2019","unstructured":"Potere N et al (2019) Low density lipoprotein receptor-related protein-1 in cardiac inflammation and infarct healing. Front Cardiovasc Med 6:51","journal-title":"Front Cardiovasc Med"},{"issue":"9","key":"5775_CR119","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.cmet.2024.05.016","volume":"36","author":"J Zhou","year":"2024","unstructured":"Zhou J et al (2024) Astrocytic LRP1 enables mitochondria transfer to neurons and mitigates brain ischemic stroke by suppressing ARF1 lactylation. Cell Metab 36(9):2054-2068.e14","journal-title":"Cell Metab"},{"issue":"8","key":"5775_CR120","doi-asserted-by":"publisher","first-page":"850","DOI":"10.3390\/genes16080850","volume":"16","author":"A Akbar","year":"2025","unstructured":"Akbar A et al (2025) CRISPR in neurodegenerative diseases treatment: an alternative approach to current therapies. Genes 16(8):850","journal-title":"Genes"},{"key":"5775_CR121","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242216288","author":"AE Alkhalifa","year":"2023","unstructured":"Alkhalifa AE et al (2023) Blood-brain barrier breakdown in Alzheimer\u2019s disease: mechanisms and targeted strategies. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms242216288","journal-title":"Int J Mol Sci"},{"issue":"11","key":"5775_CR122","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1161\/CIRCRESAHA.124.325269","volume":"135","author":"L Liu","year":"2024","unstructured":"Liu L et al (2024) LRP1 repression by SNAIL results in ECM remodeling in genetic risk for vascular diseases. Circ Res 135(11):1084\u20131097","journal-title":"Circ Res"},{"issue":"4","key":"5775_CR123","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.3390\/encyclopedia3040096","volume":"3","author":"SK Niazi","year":"2023","unstructured":"Niazi SK (2023) Gene editing: the regulatory perspective. Encyclopedia 3(4):1345\u20131357","journal-title":"Encyclopedia"},{"issue":"5","key":"5775_CR124","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/bpa.12881","volume":"30","author":"M Schrauben","year":"2020","unstructured":"Schrauben M, Dempster E, Lunnon K (2020) Applying gene-editing technology to elucidate the functional consequence of genetic and epigenetic variation in Alzheimer\u2019s disease. Brain Pathol 30(5):992\u20131004","journal-title":"Brain Pathol"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-026-05775-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-026-05775-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-026-05775-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T19:02:23Z","timestamp":1772478143000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-026-05775-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":124,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5775"],"URL":"https:\/\/doi.org\/10.1007\/s12035-026-05775-2","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"18 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent Statement"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional Review Board Statement"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"478"}}